Hello, Fool! | Login | Signup | My Fool
Dec 4, 2008 1:19 AM ET | Feedback | Site Changes | Help
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors.
View All Commentary (TRMS)
Recs
sleepyseth (96.89) Submitted: 11/07/06 4:10 PM : Start Price: $7.97 TRMS Score: -34.28
Buy this company before the earnings announcement. This will be their first quarter of steady positive earnings (actually their second positive quarter ever). The stock is down a lot over the past couple of years, but now the company is actually going to be profitable. The growth estimates look phenominal too. Hopefully the reason that the stock has gone downis not because people know something that isn't announced, but because they are just now making real money. Watch the earnings report closely, hopefully this company has bottomed.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK